Synthesis and characterization of bioactive tamoxifen-conjugated polymers

Biomacromolecules

Volumn 8, Issue 11, 2007, Pages 3608-3612

  Rickert, Emily L ^a   Trebley, Joseph P ^a,b   Peterson, Anton C ^a   Morrell, Melinda M ^a,c   Weatherman, Ross V ^a  

^a Purdue University   (United States)

^b IN Vivo Ventures   (United States)

^c Med Institute Inc Lafayette   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOM TRANSFER RADICAL POLYMERIZATION; BIOPOLYMERS; CHARACTERIZATION; LIGANDS; MACROMOLECULES; SYNTHESIS (CHEMICAL);

BIOACTIVE CONJUGATED POLYMER; MACROMOLECULAR CONJUGATES; POLYMETHACRYLIC ACID;

CONJUGATED POLYMERS;

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; LIGAND; POLYMER; POLYMETHACRYLIC ACID; TAMOXIFEN;

ARTICLE; ATOM TRANSFER RADICAL POLYMERIZATION; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; FEASIBILITY STUDY; HUMAN; HUMAN CELL; MACROMOLECULE; MOLECULAR PROBE; PRIORITY JOURNAL; RECEPTOR BINDING;

CELL LINE; ESTROGEN RECEPTOR ALPHA; HUMANS; MOLECULAR STRUCTURE; POLYMERS; TAMOXIFEN;

EID: 36749038303     PISSN: 15257797     EISSN: None     Source Type: Journal    
DOI: 10.1021/bm070413t     Document Type: Article

References (31)

1. Jordan, V. C. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discovery 2003, 2, 205-13.
2. Jordan, V. C. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 2004, 5, 207-13.
3. Normanno, N.; Di Maio, M.; De Maio, E.; De Luca, A.; de Matteis, A.; Giordano, A.; Perrone, F. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr.-Relat. Cancer 2005, 12, 721-47.
4. Maillard, S.; Ameller, T.; Gauduchon, J.; Gougelet, A.; Gouilleux, F.; Legrand, P.; Marsaud, V.; Fattal, E.; Sola, B.; Renoir, J. M. Innovative drug delivery nanosystems improve the Anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma. J. Steroid Biochem. Mol. Biol. 2005, 94, 111-21.
5. Zeisig, R.; Teppke, A. D.; Behrens, D.; Fichtner, I. Liposomal 4-hydroxy-tamoxifen: effect on cellular uptake and resulting cytotoxicity in drug resistant breast cancer cells in vitro. Breast Cancer Res. Treat 2004, 87, 245-54.
6. Olivier, J. C. Drug transport to brain with targeted panoparticles. NeuroRx 2005, 2, 108-19.
7. Harrington, W. R.; Kim, S. H.; Funk, C. C.; Madak-Erdogan, Z.; Schiff, R.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. Estrogen dendrimer conjugates that preferentially activate extranuclear, non-genornic versus genomic pathways of estrogen action. Mol. Endocrinol. 2006, 20, 491-502.
8. Rai, D.; Frolova, A.; Frasor, J.; Carpenter, A. E.; Katzenellenbogen, B. S. Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells. Mol. Endocrinol. 2005, 19, 1606-17.
9. Thomas, P.; Pang, Y.; Filardo, E. J.; Dong, J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146, 624-32.
10. Levin, E. R. Cellular functions of plasma membrane estrogen receptors. Steroids 2002, 67, 471-5.
11. O'Brien, J. E.; Peterson, T. J.; Tong, M. H.; Lee, E. J.; Pfaff, L. E.; Hewitt, S. C.; Korach, K. S.; Weiss, J.; Jameson, J. L. Estrogen-induced proliferation of uterine epithelial cells is independent of estrogen receptor alpha binding to classical estrogen response elements. J. Biol. Chem. 2006, 281, 266831-92.
12. Weatherman, R. V.; Carroll, D. C.; Scanlan, T. S. Activity of a tamoxifen-raloxifene hybrid hgand for estrogen receptors at an AP-1 site. Bioorg. Med. Client. Lett. 2001, 11, 3129-31.
13. Weatherman, R. V.; Clegg, N. J.; Scanlan, T. S. Differential SERM activation of the estrogen receptors ERalpha and ERbeta at AP-1 sites. Chem. Biol. 2001, 8, 427-36.
14. Godwin, A.; Hartenstein, M.; Muller, A. H.; Brocchini, S. Narrow molecular weight distribution precursors for polymer-drug conjugates. Angew. Chem., Int. Ed. 12001, 40, 594-597.
15. Trebley, J. P.; Rickert, E. L.; Reyes, P. T.; Weatherman, R. V. Tamoxifen-based Probes for the Study of Estrogen Receptor-Mediated Transcription. In Chemical Genomics: Small Molecule Probes to Study Cellular Function; Jaroch, S., Hilmar, W., Eds.; Springer: Berlin, 2006; Vol. 58, pp 76-87.
16. Robertson, D. W.; Katzenellenbogen, J. A.; Hayes, J. R.; Katzenellenbogen, B. S. Antiestrogen basicity-activity relationships: a comparison of the estrogen receptor binding and antiuterotrophic potencies of several analogues of (Z)-1,2-diphenyl-l-[4-[2-(dimethylamino)thoxy]phenyl]-l-butene (tarnoxifen, Nolvadex) having altered basicity. J. Med Chem. 1982, 25, 167-71.
17. Muddana, S. S.; Peterson, B. R. Facile synthesis of CIDS: biotinylated estrone oximes efficiently heterodimerize estrogen receptor and streptavidin proteins in yeast three hybrid systems. Org. Lett. 2004, 6, 1409-12.
18. Gestwicki, J. E.; Cairo, C. W.; Strong, L. E.; Oetjen, K. A.; Kiessling, L. L. Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J. Am. Chem. Soc. 2002, 124, 14922-33.
19. Criffith, B. R.; Allen, B. L.; Rapraeger, A. C.; Kiessling, L. L. A polymer scaffold for protein oligiomerization. J. Am. Chem. Soc. 2004, 126, 1608-9.
20. Lutz, J. F.; Neugebauer, D.; Matyjaszewski, K. Stereoblock copolymers and tacticity control in controlled/living radical polymerization. J. Am Chem Soc. 2003, 125, 6986-93.
21. Kuiper, G. G.; Carlsson, B.; Grandien, K.; Enmark, E.; Haggblad, J.; Nilsson, S.; Gustafsson, J. A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138, 863-70.
22. Stevis, P. E.; Deecher,,D. C.; Suhadolnik, L.; Mallis, L. M.; Frail, D. E. Differential effects of estradiol and estradiol-BSA conjugates. Endocrinology 1999, 140, 5455-5458.
23. Taguchi, Y.; Koslowski, M.; Bodenner, D. L. Binding of estrogen receptor with estrogen conjugated to bovine serum albumin BSA. Nucl. Recept. 2004, 2, 5.
24. Bulayeva, N. N.; Gametchu, B.; Watson, C. S. Quantitative measurement of estrogen-induced ERK 1 and 2 activation via multiple membrane-initiated signaling pathways. Steroids 2004, 69, 181-92.
25. Jensen, K. D.; Nori, A.; Tijerina, M.; Kopeckova, P.; Kopecek,.J. Cytoplasmic delivery and nuclear targeting of synthetic macromolecules. J. Controlled Release 2003, 87, 89-105.
26. Nori, A.; Kopecek, J. Intracellular targeting of polymer-bound drugs for cancer chemotherapy. Adv. Drug Delivery Rev. 2005, 57, 609-36.
27. Wolfert, M. A.; Dash, P. R.; Nazarova, O.; Oupicky, D.; Seymour, L. W.; Smart, S.; Strohalm, J.; Ulbrich, K. Polyelectrolyte vectors for gene delivery: influence of cationic polymer on biophysical properties of complexes formed with DNA. Bioconjugate Chem. 1999, 10, 993-1004.
28. Ulbrich, K.; Subr, V. Polymeric anticancer drugs with pH-controlled activation. Adv. Drug Delivery Rev. 2004, 56, 1023-50.
29. De Goeij, A. F.; van Zeeland, J. K.; Beek, C. J.; Bosnian, F. T. Steroid-bovine serum albumin conjugates: molecular characterization and their interaction with androgen and estrogen receptors. J. Steroid Biochem. 1986, 24, 1017-31.
30. Godeau, J. F.; Schorderetslatkine, S,; Hubert, P.; Baulieu, E. E. Induction of maturation in xenopus-laevis oocytes by a steroid linked to a polymer. Proc. Natl. Acad. Sci. U.S.A. 1978, 75, 2353-2357.
31. Hussey, S. L.; Peterson, B. R. Efficient delivery of streptavidin to mammalian cells: clathrin-mediated endocytosis regulated by a synthetic ligand. J. Am. Chem. Soc. 2002, 124, 6265-73.